• Home
  • Mail
  • Flickr
  • Tumblr
  • News
  • Sports
  • Finance
  • Entertainment
  • Lifestyle
  • Answers
  • Groups
  • More
Yahoo
    • Skip to Navigation
    • Skip to Main Content
    • Skip to Related Content

    J&J beats forecasts, helped by new medicines

    Reuters•April 15, 2014
    Products made by Johnson & Johnson for sale on a store shelf in Westminster
    Products made by Johnson & Johnson for sale on a store shelf in Westminster, Colorado April 14, 2009. REUTERS/Rick Wilking

    (Reuters) - Johnson & Johnson (NYS:JNJ) reported quarterly earnings well above Wall Street expectations, as strong sales of new prescription drugs offset weak sales of consumer products, and slightly raised its full-year profit view.

    J&J on Tuesday said it earned $4.73 billion (2.82 billion pounds), or $1.64 per share, in the first quarter. That compared with $3.5 billion, or $1.22 per share, in the year-ago quarter, when the diversified healthcare company took a big litigation charge.

    Excluding special items, J&J earned $1.54 per share. Analysts, on average, were expecting $1.48 per share, according to Thomson Reuters I/B/E/S. Sales rose 3.5 percent to $18.1 billion in the quarter, topping Wall Street forecasts of $18 billion.

    J&J says it now expects full-year earnings of $5.80 to $5.90 per share, up from its prior forecast of $5.75 to $5.85 per share given in January.

    Global sales of prescription drugs jumped almost 11 percent to $7.5 billion. Sales of Simponi, a drug for rheumatoid arthritis, rose 9.3 percent to $259 million, while sales of psoriasis treatment Stelara soared 32 percent to $456 billion.

    (Reporting by Ransdell Pierson, Editing by Franklin Paul)